Chemotherapy associated with zidovudine and Gm-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma (HIV-NHL) (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Chemotherapy associated with zidovudine and Gm-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma (HIV-NHL) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A1138 1994. Unique Identifier : AIDSLINE ICDB/94602824
Gabarre J; Lepage E; Thyss A; Bastion Y; Sebban C; Schlaifer D; Ribrag V; Fereres M; Raphael M; Gisselbrecht C; GELA, Saint-Louis Hosp., Paris, France

Abstract: HIV-NHL patients have an estimated survival according to authors between 5-9 months, a better survival can be obtained in patients with a good performance status (PS), CD4 count greater than 100 ul/mm3 and without AIDS. Main causes of death are lymphoma, opportunistic infections and therapy toxicity. In order to reduce AIDS-related mortality and maintain the intended dose of chemotherapy, a phase II study was undertaken using the intensive induction chemotherapy regimen LNH84 (Am J Med 95:188-96, 1993) with low-dose of zidovudine (5 mg/kg/day) and Gm-CSF (5 ug/kg/day; Schering-Plough). Thirty-two patients were included and their characteristics were histology-high grade lymphoma: 19 (15 Burkitt); intermediate grade: 13; stage III-IV: 19; extranodal sites greater than or equal to 2: 14 (marrow 5); LDH greater than 1N: 20; PS greater than or equal to 2: 7; CD4 less than or equal to 100: 12; prior AIDS: 4. Complete response (CR) occurred in 16 patients (50%) and partial response in 3, while 7 (22%) died during induction. Intended dose intensity was greater than 70% in 16 (57%) and less than or equal to 70% in 12. Six patients had long-lasting hematological toxicity. Among the 16 CR, 5 relapsed. Overall survival was poor (6 months). No reduction of AIDS mortality was observed. Hematological toxicity of both chemotherapy and zidovudine is insufficiently reduced with Gm-CSF.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY Bleomycin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Combined Modality Therapy Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Dose-Response Relationship, Drug Doxorubicin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Drug Administration Schedule Follow-Up Studies Granulocyte-Macrophage Colony-Stimulating Factor/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Human Lymphoma, AIDS-Related/*DRUG THERAPY/MORTALITY Prednisolone/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Survival Rate Vindesine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Zidovudine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS ABSTRACT
941230
M94C4319

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .